India’s GLP-1 drug market could reach Rs 15,700 crore by FY32, led by generics
Kotak estimates India’s GLP-1 obesity and diabetes market will grow from Rs 4,000 crore in FY27 to Rs 15,700 crore by FY32. The generic segment is projected to reach Rs 9,900 crore, creating an opportunity for Sun Pharma, Lupin, Torrent, Eris, Alkem, Zydus and Mankind.
What happened
India GLP-1 market · Kotak projects India’s GLP-1 obesity and diabetes drug market to nearly quadruple by FY32, led by lower-priced generics. Sun Pharma, Lupin,
Key facts
- GLP-1 market projected at Rs 15,700 crore by FY32, from Rs 4,000 crore in FY27
- Generic segment projected to grow from Rs 800 crore in FY27 to Rs 9,900 crore in FY32 at 65.5% CAGR
- Branded segment projected to rise from Rs 3,200 crore to Rs 5,800 crore at 12.6% CAGR
- Leading players expected to hold about 83% of generic market by FY29
- GLP-1 patient base projected to rise from 2.75 lakh to 66 lakh by FY32
- Mounjaro sales estimated at Rs 2,710 crore by FY29
Why this matters
Evaluate licensing, co-marketing and manufacturing partnerships around generic GLP-1 assets, particularly among Sun Pharma, Lupin, Torrent, Eris, Alkem, Zydus and Mankind.
What to watch
- Indian patent-expiry timelines, litigation outcomes and CDSCO approvals for semaglutide, tirzepatide and other GLP-1 therapies.
- Evidence of domestic peptide/API and injector-device capacity additions by Sun Pharma, Lupin, Torrent, Eris, Alkem, Zydus, Mankind and contract manufacturers.
- Price gaps between originator and generic products, including monthly treatment cost after introductory discounts.
- Insurance, employer-benefit or government reimbursement expansion for obesity treatment and high-risk diabetes populations.
- Prescription persistence rates, dose-escalation completion and adverse-event-driven discontinuation trends.
- Global shortages or supply normalization for branded GLP-1 products, which can respectively create or reduce room for domestic substitutes.
- New oral incretin therapies that could shift demand away from injectable products and broaden retail distribution.
- Build a GLP-1 portfolio strategy spanning diabetes, obesity and adjacent metabolic-care products rather than relying on a single molecule launch.
- Secure API, peptide manufacturing, fill-finish, pen-device and cold-chain capacity early; these capabilities may become larger bottlenecks than molecule access.
- Expand specialist engagement with diabetologists, endocrinologists, cardiologists and obesity clinics, while developing patient adherence and titration-support programs.
- Prepare differentiated generic launches using reliable supply, convenient delivery devices, multiple dosage strengths and competitive chronic-therapy pricing.
- Retail pharmacies should add cold-storage readiness, trained pharmacist counseling, prescription validation and recurring-refill programs for metabolic therapies.
- Track opportunities in companion categories including glucose monitoring, nutrition, protein supplements, gastrointestinal symptom management, diagnostics and weight-management services.